Clinical trial of ligustrazine injection combined with azithromycin sequential treatment of lobar pneumonia and protracted pneumonia
10.13699/j.cnki.1001-6821.2017.08.001
- VernacularTitle:川芎嗪注射液联合阿奇霉素序贯治疗大叶性肺炎及迁延性肺炎的临床研究
- Author:
Xiu-Jun ZHANG
1
;
Jian-Hua WANG
;
Li-Liang WEI
Author Information
1. 绍兴市立医院呼吸一科
- Keywords:
ligustrazine injection;
azithromycin sequential treatment;
lobar pneumonia;
protracted pneumonia
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(8):675-677,680
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of ligustrazine injection combined with azithromycin sequential therapy of lobar pneumonia and protracted pneumonia.Methods A total of 68 patients with lobar pneumonia and protracted pneumonia were randomly divided into control group and treatment group,with 34 cases in each group.Patients in both groups were given conventional treatment and symptomatic treatment.Patients in control group were given azithromycin sequential treatment,azithromycin injection 10 mg· kg-1 intravenous drip,continuous 3-5 d,body temperature and peripheral blood leukocytes returned to normal range,with azithromycin dry suspension 10 mg· kg-1,1 time a day.Paticnts in treatment group were given ligustrazine hydrochloride injection 40 mg +0.9％ NaC1 250-500 mL intravenous drip,1 time a day on the basis of control group.All patients were treated for 10 d.The clinical efficacy,serum interleukin (IL)-6,IL-8,IL-10,T lymphocyte subgroup and adverse drug reactions in two groups were compared.Results After treatment,the total effective rate in treatment group was 88.32％ (30/34 cases),significandy higher than that in control group,which was 64.71％ (22/34 cases,P ＜0.05).After treatment,the IL-6 in control group and treatment group were (40.39 ±4.87),(21.08± 2.90) pg · mL-1;IL-8 were (43.29 ± 5.22),(27.93 ± 3.19) pg · mL-1,IL-10 were (31.93 ± 3.53),(18.02 ± 2.45) pg · mL-1,with significant difference (P ＜ 0.05).After treatment,the CD3 + in control group and treatment group were (63.49 ±7.41),(77.92 ± 8.41)％,CD4 + were (30.20 ± 3.58),(35.83 ±4.71)％,CD8 + were (27.38 ±3.49),(23.07 ±3.01)％,CD4+/CD8+were 1.18 ±0.21,1.32 ±0.16,with significant difference (P ＜ 0.05).The adverse reaction in treatment group were mild gastrointestinal reaction,chest tightness,hypotension,total incidence rate of adverse reaction was 8.82％ (3/34 cases).The adverse reactions in control group were mild gastrointestinal reactions,drowsiness,chest tightness,skin rash,total incidence rate of adverse reaction was 17.65％ (6/34 cases,P ＞0.05).Conclusion Ligustrazine injection combine with azithromycin sequential treatment of lobar pneumonia and protracted pneumonia has higher clinical efficacy,high safety.
